The SIRT1 activator SRT1720 extends lifespan and improves health of mice fed a standard diet

Cell Reports

Volumn 6, Issue 5, 2014, Pages 836-843

  Mitchell, Sarah J ^a,b,c   Martin Montalvo, Alejandro ^a   Mercken, Evi M ^a   Palacios, Hector H ^a   Ward, Theresa M ^a   Abulwerdi, Gelareh ^a   Minor, Robin K ^a   Vlasuk, George P ^d   Ellis, James L ^d   Sinclair, David A ^e   Dawson, John ^f   Allison, David B ^f   Zhang, Yongqing ^a   Becker, Kevin G ^a   Bernier, Michel ^a   De Cabo, Rafael ^a  

^a NATIONAL INSTITUTE ON AGING   (United States)

^b ROYAL NORTH SHORE HOSPITAL   (Australia)

^c UNIVERSITY OF SYDNEY   (Australia)

^d GLAXOSMITHKLINE   (United States)

^e HARVARD MEDICAL SCHOOL   (United States)

^f UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ENZYME ACTIVATOR; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; SIRTUIN 1; SRT 1720; UNCLASSIFIED DRUG; ASPARTATE AMINOTRANSFERASE; CREATINE KINASE; CREATININE; CYCLOOXYGENASE 2; GLUCOSE; INSULIN; LOW DENSITY LIPOPROTEIN; N [2 [3 (1 PIPERAZINYLMETHYL)IMIDAZO[2,1 B]THIAZOL 6 YL]PHENYL] 2 QUINOXALINECARBOXAMIDE; NEUTROPHIL GELATINASE ASSOCIATED LIPOCALIN; PROTEIN BAX; TRANSCRIPTION FACTOR RELA; TUMOR NECROSIS FACTOR ALPHA; FUSED HETEROCYCLIC RINGS; TRANSCRIPTOME;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; DIET SUPPLEMENTATION; ENZYME ACTIVATION; GENE EXPRESSION; HEALTH STATUS; IN VITRO STUDY; LIFE EXTENSION; LIPID DIET; LIPID METABOLISM; MALE; METABOLIC DISORDER; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; ONSET AGE; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; SURVIVAL RATE; THERAPY EFFECT; TREATMENT OUTCOME; ADULT; ANIMAL CELL; ANKRD1 GENE; BODY FAT; CALORIC INTAKE; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DEATH; DOWN REGULATION; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG RESPONSE; EMBRYO; FATTY ACID OXIDATION; GENE; GENE EXPRESSION REGULATION; GLOMERULONEPHRITIS; HOMEOSTATIC MODEL ASSESSMENT OF INSULIN RESISTANCE; INSULIN SENSITIVITY; LCN2 GENE; LIVER CELL CARCINOMA; LUNG GAS EXCHANGE; METABOLIC PARAMETERS; METABOLIC SYNDROME X; MOTOR COORDINATION; MUSCLE FUNCTION; ORAL GLUCOSE TOLERANCE TEST; RISK FACTOR; SAA1 GENE; SAA2 GENE; SENILE CATARACT; STEATOSIS; SURVIVAL; TREATMENT DURATION; WEIGHT REDUCTION; ANIMAL; C57BL MOUSE; DIET; GENETICS; LONGEVITY; METABOLISM;

ANIMALIA; MUS;

ANIMALS; DIET; HETEROCYCLIC COMPOUNDS WITH 4 OR MORE RINGS; LONGEVITY; MALE; MICE; MICE, INBRED C57BL; SIRTUIN 1; SURVIVAL ANALYSIS; TRANSCRIPTOME;

EID: 84895925833     PISSN: None     EISSN: 22111247     Source Type: Journal    
DOI: 10.1016/j.celrep.2014.01.031     Document Type: Article

References (43)

1. Banks A.S., Kon N., Knight C., Matsumoto M., Gutiérrez-Juárez R., Rossetti L., Gu W., Accili D. SirT1 gain of function increases energy efficiency and prevents diabetes in mice. Cell Metab. 2008, 8:333-341.
2. Baur J.A., Pearson K.J., Price N.L., Jamieson H.A., Lerin C., Kalra A., Prabhu V.V., Allard J.S., Lopez-Lluch G., Lewis K., et al. Resveratrol improves health and survival of mice on a high-calorie diet. Nature 2006, 444:337-342.
3. Baur J.A., Ungvari Z., Minor R.K., Le Couteur D.G., de Cabo R. Are sirtuins viable targets for improving healthspan and lifespan?. Nat. Rev. Drug Discov. 2012, 11:443-461.
4. Bellet M.M., Nakahata Y., Boudjelal M., Watts E., Mossakowska D.E., Edwards K.A., Cervantes M., Astarita G., Loh C., Ellis J.L., et al. Pharmacological modulation of circadian rhythms by synthetic activators of the deacetylase SIRT1. Proc. Natl. Acad. Sci. USA 2013, 110:3333-3338.
5. Bernier M., Paul R.K., Martin-Montalvo A., Scheibye-Knudsen M., Song S., He H.J., Armour S.M., Hubbard B.P., Bohr V.A., Wang L., et al. Negative regulation of STAT3 protein-mediated cellular respiration by SIRT1 protein. J.Biol. Chem. 2011, 286:19270-19279.
6. Chauhan D., Bandi M., Singh A.V., Ray A., Raje N., Richardson P., Anderson K.C. Preclinical evaluation of a novel SIRT1 modulator SRT1720 in multiple myeloma cells. Br. J. Haematol. 2011, 155:588-598.
7. Cheadle C., Vawter M.P., Freed W.J., Becker K.G. Analysis of microarray data using Z score transformation. J.Mol. Diagn. 2003, 5:73-81.
8. de Jong E., Winkel P., Poelstra K., Prakash J. Anticancer effects of 15d-prostaglandin-J2 in wild-type and doxorubicin-resistant ovarian cancer cells: novel actions on SIRT1 and HDAC. PLoS ONE 2011, 6:e25192.
9. Deblon N., Bourgoin L., Veyrat-Durebex C., Peyrou M., Vinciguerra M., Caillon A., Maeder C., Fournier M., Montet X., Rohner-Jeanrenaud F., Foti M. Chronic mTOR inhibition by rapamycin induces muscle insulin resistance despite weight loss in rats. Br. J. Pharmacol. 2012, 165:2325-2340.
10. Dominy J., Puigserver P., Cantó C. Invivo measurement of the acetylation state of sirtuin substrates as a proxy for sirtuin activity. Methods Mol. Biol. 2013, 1077:217-237.
11. Feige J.N., Lagouge M., Canto C., Strehle A., Houten S.M., Milne J.C., Lambert P.D., Mataki C., Elliott P.J., Auwerx J. Specific SIRT1 activation mimics low energy levels and protects against diet-induced metabolic disorders by enhancing fat oxidation. Cell Metab. 2008, 8:347-358.
12. Franceschi C., Bonafè M., Valensin S., Olivieri F., De Luca M., Ottaviani E., De Benedictis G. Inflamm-aging. An evolutionary perspective on immunosenescence. Ann. N Y Acad. Sci. 2000, 908:244-254.
13. Froy O. Circadian rhythms, aging, and life span in mammals. Physiology (Bethesda) 2011, 26:225-235.
14. Hafner M., Rezen T., Rozman D. Regulation of hepatic cytochromes p450 by lipids and cholesterol. Curr. Drug Metab. 2011, 12:173-185.
15. Harrison D.E., Strong R., Sharp Z.D., Nelson J.F., Astle C.M., Flurkey K., Nadon N.L., Wilkinson J.E., Frenkel K., Carter C.S., et al. Rapamycin fed late in life extends lifespan in genetically heterogeneous mice. Nature 2009, 460:392-395.
16. Heeren G., Rinnerthaler M., Laun P., von Seyerl P., Kössler S., Klinger H., Hager M., Bogengruber E., Jarolim S., Simon-Nobbe B., et al. The mitochondrial ribosomal protein of the large subunit, Afo1p, determines cellular longevity through mitochondrial back-signaling via TOR1. Aging (Albany, N.Y. Online) 2009, 1:622-636.
17. Houde V.P., BrÛlé S., Festuccia W.T., Blanchard P.G., Bellmann K., Deshaies Y., Marette A. Chronic rapamycin treatment causes glucose intolerance and hyperlipidemia by upregulating hepatic gluconeogenesis and impairing lipid deposition in adipose tissue. Diabetes 2010, 59:1338-1348.
18. Houtkooper R.H., Mouchiroud L., Ryu D., Moullan N., Katsyuba E., Knott G., Williams R.W., Auwerx J. Mitonuclear protein imbalance as a conserved longevity mechanism. Nature 2013, 497:451-457.
19. Hubbard B.P., Gomes A.P., Dai H., Li J., Case A.W., Considine T., Riera T.V., Lee J.E., e S.Y., Lamming D.W., et al. Evidence for a common mechanism of SIRT1 regulation by allosteric activators. Science 2013, 339:1216-1219.
20. Huber J.L., McBurney M.W., Distefano P.S., McDonagh T. SIRT1-independent mechanisms of the putative sirtuin enzyme activators SRT1720 and SRT2183. Future Med Chem 2010, 2:1751-1759.
21. Ichikawa T., Hayashi R., Suzuki K., Imanishi S., Kambara K., Okazawa S., Inomata M., Yamada T., Yamazaki Y., Koshimizu Y., et al. Sirtuin 1 activator SRT1720 suppresses inflammation in an ovalbumin-induced mouse model of asthma. Respirology 2013, 18:332-339.
22. Kovács A.D., Pearce D.A. Location- and sex-specific differences in weight and motor coordination in two commonly used mouse strains. Sci Rep 2013, 3:2116.
23. Kubo M., Hanada T., Yoshimura A. Suppressors of cytokine signaling and immunity. Nat. Immunol. 2003, 4:1169-1176.
24. Lamming D.W., Ye L., Katajisto P., Goncalves M.D., Saitoh M., Stevens D.M., Davis J.G., Salmon A.B., Richardson A., Ahima R.S., et al. Rapamycin-induced insulin resistance is mediated by mTORC2 loss and uncoupled from longevity. Science 2012, 335:1638-1643.
25. Lee C., Raffaghello L., Brandhorst S., Safdie F.M., Bianchi G., Martin-Montalvo A., Pistoia V., Wei M., Hwang S., Merlino A., et al. Fasting cycles retard growth of tumors and sensitize a range of cancer cell types to chemotherapy. Sci. Translat. Med. 2012, 4:124ra127.
26. Martin-Montalvo A., Mercken E.M., Mitchell S.J., Palacios H.H., Mote P.L., Scheibye-Knudsen M., Gomes A.P., Ward T.M., Minor R.K., Blouin M.J., et al. Metformin improves healthspan and lifespan in mice. Nat Commun 2013, 4:2192.
27. Milne J.C., Lambert P.D., Schenk S., Carney D.P., Smith J.J., Gagne D.J., Jin L., Boss O., Perni R.B., Vu C.B., et al. Small molecule activators ofSIRT1 as therapeutics for the treatment of type 2 diabetes. Nature 2007, 450:712-716.
28. Minor R.K., Baur J.A., Gomes A.P., Ward T.M., Csiszar A., Mercken E.M., Abdelmohsen K., Shin Y.K., Canto C., Scheibye-Knudsen M., et al. SRT1720 improves survival and healthspan of obese mice. Sci Rep 2011, 1:70.
29. Oh W.K., Cho K.B., Hien T.T., Kim T.H., Kim H.S., Dao T.T., Han H.K., Kwon S.M., Ahn S.G., Yoon J.H., et al. Amurensin G, a potent natural SIRT1 inhibitor, rescues doxorubicin responsiveness via down-regulation of multidrug resistance 1. Mol. Pharmacol. 2010, 78:855-864.
30. Pacholec M., Bleasdale J.E., Chrunyk B., Cunningham D., Flynn D., Garofalo R.S., Griffith D., Griffor M., Loulakis P., Pabst B., et al. SRT1720, SRT2183, SRT1460, and resveratrol are not direct activators of SIRT1. J.Biol. Chem. 2010, 285:8340-8351.
31. Pearson K.J., Baur J.A., Lewis K.N., Peshkin L., Price N.L., Labinskyy N., Swindell W.R., Kamara D., Minor R.K., Perez E., et al. Resveratrol delays age-related deterioration and mimics transcriptional aspects of dietary restriction without extending life span. Cell Metab. 2008, 8:157-168.
32. Pfluger P.T., Herranz D., Velasco-Miguel S., Serrano M., Tschöp M.H. Sirt1 protects against high-fat diet-induced metabolic damage. Proc. Natl. Acad. Sci. USA 2008, 105:9793-9798.
33. Rogers A.N., Chen D., McColl G., Czerwieniec G., Felkey K., Gibson B.W., Hubbard A., Melov S., Lithgow G.J., Kapahi P. Life span extension via eIF4G inhibition is mediated by posttranscriptional remodeling of stress response gene expression in C. elegans. Cell Metab. 2011, 14:55-66.
34. Strong R., Miller R.A., Astle C.M., Baur J.A., de Cabo R., Fernandez E., Guo W., Javors M., Kirkland J.L., Nelson J.F., et al. Evaluation of resveratrol, green tea extract, curcumin, oxaloacetic acid, and medium-chain triglyceride oil on life span of genetically heterogeneous mice. J.Gerontol. A Biol. Sci. Med. Sci. 2013, 68:6-16.
35. Su J.Q., Wei L.J. Nonparametric estimation for the difference or ratio of median failure times. Biometrics 1993, 49:603-607.
36. Suzuki K., Hayashi R., Ichikawa T., Imanishi S., Yamada T., Inomata M., Miwa T., Matsui S., Usui I., Urakaze M., et al. SRT1720, a SIRT1 activator, promotes tumor cell migration, and lung metastasis of breast cancer in mice. Oncol. Rep. 2012, 27:1726-1732.
37. Tong C., Morrison A., Mattison S., Qian S., Bryniarski M., Rankin B., Wang J., Thomas D.P., Li J. Impaired SIRT1 nucleocytoplasmic shuttling in the senescent heart during ischemic stress. FASEB J. 2013, 27:4332-4342.
38. Wang C., Li Q., Redden D.T., Weindruch R., Allison D.B. Statistical methods for testing effects on "maximum lifespan". Mech. Ageing Dev. 2004, 125:629-632.
39. Wolf N., Penn P., Pendergrass W., Van Remmen H., Bartke A., Rabinovitch P., Martin G.M. Age-related cataract progression in five mouse models for anti-oxidant protection or hormonal influence. Exp. Eye Res. 2005, 81:276-285.
40. Yamazaki Y., Usui I., Kanatani Y., Matsuya Y., Tsuneyama K., Fujisaka S., Bukhari A., Suzuki H., Senda S., Imanishi S., et al. Treatment with SRT1720, a SIRT1 activator, ameliorates fatty liver with reduced expression of lipogenic enzymes in MSG mice. Am. J. Physiol. Endocrinol. Metab. 2009, 297:E1179-E1186.
41. Yao H., Chung S., Hwang J.W., Rajendrasozhan S., Sundar I.K., Dean D.A., McBurney M.W., Guarente L., Gu W., Rönty M., et al. SIRT1 protects against emphysema via FOXO3-mediated reduction of premature senescence in mice. J.Clin. Invest. 2012, 122:2032-2045.
42. Zeng H.T., Fu Y.C., Yu W., Lin J.M., Zhou L., Liu L., Wang W. SIRT1 prevents atherosclerosis via liver-X-receptor and NF-κB signaling in a U937 cell model. Mol Med Rep 2013, 8:23-28.
43. Zhu H., Xia L., Zhang Y., Wang H., Xu W., Hu H., Wang J., Xin J., Gang Y., Sha S., et al. Activating transcription factor 4 confers a multidrug resistance phenotype to gastric cancer cells through transactivation of SIRT1 expression. PLoS ONE 2012, 7:e31431.